Back
Expanded hemodialysis (HDx), enabled by medium cut-off dialyzers, has been shown to increase the clearance of large middle molecules, compared to high flux hemodialysis (HF HD). Clearance of large middle molecular uremic toxins resulted in improved clinical outcomes. Patients and healthcare providers highly value the effects of new therapy on patient’s quality of life.
The aim of this study was to compare PROMs at baseline with HF HD (before phase) and a second measurement one month after the change to HDX (after phase) in twelve dialysis clinics in Colombia
This is an observational multicenter retrospective cohort study. Prevalent patients on dialysis for at least 90 days, older than eighteen, at the Baxter Renal Care Services Colombia were included between August 1, 2023, and September 15, 2023, with a 4-week follow-up. The sociodemographic and clinical characteristics of all patients were summarized. In addition, dialysis recovery time, diagnostic criteria for restless legs, and pruritus scale were measured. Pearson’s χ2 test was used for differences in proportions and Mann Whitney U test for differences in means.
A total of 737 patients were included in the analysis; the mean age was 65 years, 14.8% had diabetic kidney disease, the vintage in KRT was 4.2 years, and the proportion of patients with protein energy wasting (PEW) was 20% (Table 1).
We observed a shorter recovery time using Theranova dialyzer (Table 2).
Conclusions
Patients who were treated with expanded hemodialysis enabled by Theranova had improved recovery time, pruritus index score and restless leg syndrome. The results of this study should be corroborated in an RCT.